Soluble TCR Expression Services | TCR & SPR Analysis

Custom Soluble TCR Expression Service Overview

We're pleased to offer specialized custom services related to MHC and TCR research, including the expression of TCRs, and TCR-related drugs. Researchers often need TCRs in order to study their role in immune responses, to develop TCR-based therapies, and to screen for potential therapeutic candidates. In support of this, we offer custom expression services for soluble TCRs and soluble TCR fusion proteins. Additionally, we can perform analysis services including matured affinity TCR ELISAs and low affinity TCR SPR assays.

TCR Expression & Engineering Service Features

Production of various formats of soluble TCRs, including scFv-TCR, TCR-His, etc.

TCR engineering to optimize soluble TCR expression based on TCR modeling

SPR or ELISA analysis of soluble TCR & MHC interactions

Performance Validation of Expressed TCRs & Affinity Testing

Our Soluble TCR Expression Services can be paired with our SPR analysis services, where we perform MHC binding affinity analysis for your TCRs. Alternatively, you can try our peptide-ready MHC (prMHC) products to load custom peptides onto an MHC monomer or tetramer in-house and conduct your own TCR binding assays. Let us know in your quote request if you're interested in any additional validation options!

Request Quote

Request Quote:

Case Studies & Applications

GP100 TCR & Anti-CD3 Bispecific Fusion

We have successfully expressed a GP100 TCR & Anti-CD3 Bispecific Fusion, which can not only bind to HLA-A*02:01&B2M&GP100 (YLEPGPVTA) complex, but also to CD3 heterodimers at the same time, demonstrating good bispecific binding activity.

Figure 1. In SPR analysis, the GP100 TCR & Anti-CD3 Bispecific Fusion can bind to the HLA-A*02:01&B2M&GP100 (YLEPGPVTA) complex tetramer, with an affinity constant of 0.196 nM.

Figure 2. ELISA verification demonstrates that GP100 TCR & Anti-CD3 Bispecific Fusion can bind to HLA-A*02:01&B2M&GP100 (YLEPGPVTA) complex monomer with an EC50 of 11.8 ng/mL.

Figure 3. ELISA verification demonstrates that GP100 TCR & Anti-CD3 Bispecific Fusion can bind to Human CD3E&CD3D, with an EC50 value of 8.7 ng/mL.

Figure 4. ELISA verification demonstrates that GP100 TCR & Anti-CD3 Bispecific Fusion can bind to Human CD3E&CD3G, with an EC50 value of 0.22 μg/mL.

AFP-Specific TCR

We expressed an HLA-A*02:01&B2M&AFP (FMNKFIYEI) TCR which can successfully bind to our single-chain trimer MHC-peptide complex and our prMHC loaded with AFP peptide (FMNKFIYEI).

MHC SPR Data on HLA-A*02:01 Monomer & FMNKFIYEI

Figure 5. Single-chain trimer MHC, Human HLA-A*02:01&B2M&AFP (FMNKFIEl) Monomer, His-Avi Tag captured on CM5 Chip via Anti-His Antibody, can bind HLA-A*02:01&B2M&AFP (FMNKFIYEI) TCR with an affinity constant of 0.3991 µM as determined in SPR assay (Biacore T200).

Figure 6. Peptide-ready MHC, Human HLA-A*02:01&B2M, His-Avi Tag loaded with FMNKFIYEI peptide, captured on CM5 Chip via Anti-His Antibody, can bind HLA-A*02:01&B2M&AFP (FMNKFIYEI) TCR with an affinity constant of 0.326 µM as determined in SPR assay (Biacore T200).

Request Quote